Affiliation: University of Pennsylvania
Dennis Discher is one of the most influential researchers in cellular mechanobiology. In a landmark 2013
Science paper, his group showed that lamin A levels scale with the stiffness and mechanical demands of
tissues and influence matrix-directed cell differentiation. The study provided a powerful general
explanation for why abnormalities in lamin A/C can have their strongest effects in mechanically active
tissues such as skeletal muscle and the heart. Although the work was not limited to EDMD, it
fundamentally shaped how researchers think about lamins as adaptive regulators of nuclear mechanics.
Affiliation: National Cancer Institute, National Institutes of Health
Tom Misteli is a pioneer in genome cell biology and the study of how three-dimensional nuclear
organization affects gene regulation and disease. His group has mapped changes in chromatin organization
and lamin interactions caused by abnormal lamin A, particularly in progeria and other laminopathies.
Although this work is not specific to EDMD, it established methods and concepts for understanding how
LMNA variants can alter genome organization rather than acting only through mechanical weakness. This
broader genome-organization perspective remains highly relevant to muscle differentiation and disease
progression in EDMD.
Affiliation: Sorbonne Université, INSERM, and the Institut de Myologie, Paris
Antoine Muchir was the lead experimental investigator on the influential study identifying early MAPK
activation in an LMNA EDMD model. His subsequent work showed that pharmacologic inhibition of pathways
such as ERK and JNK could reduce fibrosis, improve cardiac function, or delay cardiomyopathy in
experimental models. These studies provided some of the earliest evidence that a molecular pathway
downstream of lamin dysfunction could be therapeutically targeted. His group continues to investigate
signaling, calcium regulation, fibrosis, and other modifiable mechanisms in striated-muscle
laminopathies.
Affiliation: University of California, Los Angeles
Stephen Young's laboratory has developed and characterized influential genetic models of nuclear-lamin
disease. In a widely cited 2006 study with Jan Lammerding and collaborators, the researchers demonstrated
that lamins A and C, but not lamin B1, are major determinants of nuclear mechanical stiffness. The result
clarified the specific structural role of A-type lamins and helped explain the nuclear fragility observed
in LMNA muscular dystrophies. His mouse models and molecular studies remain important tools for research
on laminopathies, cardiomyopathy, and nuclear-envelope function.
Investigating how nuclear-envelope proteins affect muscle cells and exploring LINC complex disruption as a potential treatment approach.
Affiliation: Cornell University
Jan Lammerding is a professor in the Meinig School of Biomedical Engineering and the Weill Institute for Cell and Molecular Biology at Cornell University. He was appointed as the Associate Director of the Meinig School of Biomedical Engineering in 2024. He obtained a Diplom Ingenieur degree in Mechanical Engineering in his native Germany and a Bachelor of Engineering degree from the Thayer School of Engineering at Dartmouth College. Subsequently, he completed his Ph.D. in Biological Engineering at the Massachusetts Institute of Technology studying subcellular biomechanics and mechanotransduction signaling with Drs. Roger Kamm and Richard T. Lee (Brigham and Women’s Hospital/Harvard Medical School). Following a brief postdoctoral fellowship in Dr. Lee’s laboratory, he started his faculty career at Harvard Medical School/Brigham and Women’s Hospital while also teaching in the Department of Biological Engineering at the Massachusetts Institute for Technology before joining Cornell University in 2011.
Dr. Lammerding has published over 100 peer-reviewed articles, including in Nature, Science, and PNAS. He has won several prestigious awards, including the Keith Porter award of the American Society for Cell Biology (ASCB) for exceptional contributions to cell biology, a National Science Foundation CAREER Award, and the American Heart Association Scientist Development Grant. He was named one of the 2014 Young Innovators by the Cell and Molecular Bioengineering Journal. Dr. Lammerding is a Fellow of the Biomedical Engineering Society (BMES), the American Institute for Medical and Biological Engineering (AIMBE), and the American Society for Cell Biology (ASCB). The research in the Lammerding laboratory is supported by grants from the National Institutes of Health, the National Science Foundation, the Leducq Foundation, and the Volkswagen Foundation.
The Lammerding laboratory at Cornell University is researching the cellular functions affected by emerin and lamins, the nuclear-lamina proteins that are missing or faulty in EDMD, with the goal to identify novel therapeutic strategies to intervene in the mechanisms responsible for EDMD to treat the disease. One promising area of the lab’s research is called “LINC complex disruption”. The Linker of Nucleoskeleton and Cytoskeleton (LINC) complex is a large multi-protein structure that physically connects the cell nucleus with the surrounding cellular structures. The lab has found that disrupting the LINC complex shows very promising improvements in muscle function both in laboratory-cultured diseased muscle cells and in mouse models of EDMD (i.e., mice genetically engineered to have similar mutations as in human EDMD patients, thereby serving as ‘preclinical’ models to study the disease and to test new treatment approaches). In collaboration with researchers at Stanford University, the University of Pennsylvania, Duke University and the Institute of Myology/INSERM (Paris, France), supported in part through Networks of Excellence funded by the Leducq Foundation, the Lammerding lab is working to identify drugs that can target the LINC complex or achieve similar benefits as LINC complex disruption.
In parallel, the Lammerding lab is exploring additional treatment approaches that could substitute or complement LINC complex disruption to result in even more effective improvements. As this work progresses, the lab is investigating whether existing, FDA-approved drugs could be used off-label to help EDMD patients.
The work of the Lammerding Lab has real potential to benefit EDMD patients in the coming years and is therefore a high priority for cureEDMD. Based on our current understanding of the disease mechanism, there is good reason to believe that any therapeutic progress on EDMD might also provide benefit for other laminopathies, including limb-girdle muscular dystrophy, congenital muscular dystrophy, and LMNA-associated dilated cardiomyopathy.
Gregorio Valdez studies the nervous system and skeletal muscles, including neuromuscular junctions, aging, and muscular dystrophy.
Affiliation: University of Iowa Carver College of Medicine
Lori Wallrath develops fruit-fly models carrying patient-associated lamin mutations to investigate
skeletal-muscle and cardiac laminopathies. Her models have revealed abnormalities in nuclear
organization, nucleo-cytoskeletal coupling, oxidative stress, protein aggregation, and muscle function,
creating a tractable system for testing genetic and pharmacological modifiers. She also contributed to
the influential 2020 study showing that mutant lamins cause mechanically induced nuclear-envelope rupture
and DNA damage in skeletal muscle. Her work is particularly valuable because it connects fundamental
lamin biology with rapid in vivo screening for potentially modifiable disease pathways.
Studying disease pathways in heart and skeletal muscle and developing gene therapy approaches to restore emerin.
Affiliation: Columbia University
Howard J. Worman, M.D. is Professor of Medicine and Pathology and Cell Biology at Columbia University and Attending Physician at New York-Presbyterian Hospital Columbia University Irving Medical Center. Dr. Worman received his BA from Cornell University and MD from the University of Chicago. He did an internship and residency in internal medicine at New York Hospital-Cornell Medical Center and a postdoctoral research fellowship in cell biology at Rockefeller University, where he started his research on the nuclear envelope.
Dr. Worman is internationally recognized for his nearly 40 years of research on the nuclear envelope and its role in disease, including Emery-Dreifuss muscular dystrophy (EDMD). In 1993, his laboratory characterized the human lamin A/C gene, which is mutated in autosomal dominant EDMD. In 1999, his group published one of the first studies of how emerin, the protein lacking in X-linked EDMD, is targeted to the nuclear envelope inner membrane. In 2013, his laboratory showed that emerin deficiency significantly worsened the muscular dystrophy in mice lacking lamina-associated polypeptide 1 from skeletal muscle, thus establishing the only vertebrate model system to date in which the effects of emerin disruption on muscle pathology can be studied (unlike humans, mice without emerin to not develop muscular dystrophy). Using various mouse and cellular models, Dr. Worman’s laboratory has conducted numerous studies dissecting gene expression and cell signaling abnormalities in heart and skeletal muscle that occur in EDMD. His laboratory has also tested several potential therapies in mouse models of EDMD.
Dr. Worman’s current research on EDMD is aimed at deciphering the common transcriptomic, proteomic and metabolomic alterations in heart cells with deletions of the genes encoding lamin A/C and emerin. This research could uncover potential therapeutic targets for two different inherited types of EDMD. He is using mouse models to determine how depletion of lamin A/C from mature skeletal muscle fibers and satellite cells – the cells responsible for muscle regeneration – contribute to pathology in autosomal dominant EDMD. His laboratory is also working on developing gene therapy to restore emerin expression in heart and skeletal muscle that could be translated to patients with X-linked EDMD.
Dr. Worman is an author on over 225 scientific publications. In 1998, he was elected to membership in the American Society for Clinical Investigator and, in 2010, to the Association of American Physicians. He has served as a member of numerous NIH review panels, the MDA Medical Advisory Committee and the NIH Action Plan for the Muscular Dystrophies Mechanisms of Muscular Dystrophy Working Group. In addition to his academic activities, Dr. Worman is a consultant for pharmaceutical, biotechnology and clinical genomics companies, including those developing gene therapies, other treatments and diagnostics for muscular dystrophies.